Neurocrine BiosciencesNASDAQ: NBIX

Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA® (valbenazine) capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Todd Tushla - Vice President of Investor Relations Conference Call Participants Chris Shibutani - Goldman Sachs Paul Matteis - Stifel David Ansellem - Piper Sandler Phoebe Tan - Jefferies Tazeen Ahmad - Bank of America Securities Jay Olson - Oppenheimer Ash Verma - UBS Philip Nadeau - TD Cowen Anupam Rama - J.P. Morgan Evan Seigerman - BMO Capital Markets Cory Kasimov - Evercore ISI Carter Gould - Barclays Mohit Bansal - Wells Fargo Marc Goodman - Leerink Partners Myles Minter - William Blair Michael Riad - Morgan Stanley Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Uy Ear - Mizuho Securities Ami Fadia - Needham Operator Good day, everyone and welcome to Neurocrine Biosciences' reports Third Quarter Results.

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications, FDA Priority Review for crinecerfont in congenital adrenal hyperplasia, a deep neuroscience focused pipeline and a strong balance sheet, we are confident in our ability to help more patients than ever before," said Kyle W.

Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects Neurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive Disorder SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.

The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.

Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.